Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Will Distribute Gene Logic s Expression-Analysis System ...

NEW YORK, July 19 (GenomeWeb News) - GE Healthcare will be the global distributor for Gene Logic's Sciantis online gene expression-analysis system, Gene Logic said today.


News of the deal caused shares in Gene Logic to climb 7.7 percent, or $.28, to $3.96 in heavy mid-afternoon trading today.The stock briefly reached $4.21 in late-morning trade but leveled off soon after.


Under the terms of the agreement, GE Healthcare will distribute Sciantis in 32 countries, and will be the exclusive distributor in Japan.


Financial terms of the deal were not disclosed.


Gene Logic said that Sciantis was developed for use by researchers in academia, government, and research organizations. The browser-based gene-expression application, based on Gene Logic's gene-expression reference database, enables researchers to profile the expression of more than 6,000 human, rat, and mouse genes in normal and diseased tissue, Gene Logic said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.